Bardan I, Uhlig T, Sexton J, Kvien TK, Bakland G, Mielnik P, Hu Y, Molberg Ø, Aga AB, Kristianslund EK (2026)
Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug-Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population
J Rheumatol, 53 (1), 77-84
DOI 10.3899/jrheum.2025-0384, PubMed 40890003

Foeldvari I, Torok K, Kasapcopur O, Adrovic A, Feldman B, Sztajnbok F, Terreri MT, Sakamoto AP, Johnson S, Anton J, Stanevicha V, Khan A, Schonenberg-Meinema D, Al-Abadi E, Alexeeva E, Katsicas M, Sawhney S, Smith V, Appenzeller S, Avcin T, Kostik M, Lehman T, Malcova H, Marrani E, Pain CE et al. (2026)
What is the treatment pattern of juvenile systemic sclerosis? Results from an international cohort
J Scleroderma Relat Disord, 11 (1), e000010
DOI 10.1136/jsrd-2026-000010, PubMed 42256629

Hetlevik SO, Lilleby V, Pesonen M, Nordal E, Rygg M, Austad C, Jonsson MK, Bilstad M, Høiberg HK, Sande NK, Flatø B, Lillegraven S, Haavardsholm EA, Ramanan AV, Molberg Ø, Bøyesen P, Aga AB (2026)
Moving towards optimized treatment for children and adolescents with juvenile idiopathic arthritis in sustained remission randomized to continue stable treatment, methotrexate withdrawal or tumor necrosis factor inhibitor withdrawal: study protocol for the Norwegian multi-center MOVE-JIA trial
Trials, 27 (1)
DOI 10.1186/s13063-026-09539-0, PubMed 41703606